Understanding how MAST1 contributes to resistance against cisplatin in cancer treatment
Official title: Dissecting and Targeting MAST1 Signaling in chemoresistant Cancers
Funded at Emory University · NIH-10999650 · Data updated 2026-11-12
This study is looking at a protein called MAST1 that helps some cancer cells resist a common chemotherapy drug called cisplatin, and by understanding how it works, the researchers hope to find better ways to make this treatment more effective for patients, especially those with certain gene mutations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | July 17, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $434,313 |
| NIH project number | 1R01CA287782-01A1 |
| Project ID | NIH-10999650 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with cancers that are known to be treated with cisplatin and who exhibit resistance to this drug.
✕Less likely to help
Patients with cancers that are not treated with cisplatin or those who do not exhibit chemoresistance may not benefit from this research.
What this research studies
This research investigates the role of MAST1, a protein that contributes to resistance against cisplatin, a common chemotherapy drug used to treat various cancers. By using advanced techniques such as RNA interference and proteomics, the study aims to uncover how MAST1 is activated and regulated, particularly in cancers with mutations in the p53 gene. The researchers are also exploring the relationship between MAST1 and cancer cell metabolism, which could lead to new therapeutic strategies to overcome drug resistance. Patients may benefit from insights that could improve the effectiveness of cisplatin and similar treatments.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the effectiveness of cisplatin in patients with chemoresistant cancers.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways to overcome drug resistance in cancer treatment, indicating that this approach has potential.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Kang, Sumin — Emory University
- Study coordinator: Kang, Sumin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.